The Effect of Serotonin-Norepinephrine Reuptake Inhibitor Milnacipran on Anxiety-like Behaviors in Diabetic Mice

Background: Diabetes mellitus is a chronic disease that causes neuronal plasticity and increased hypothalamic pituitary adrenal (HPA) axis of stress disorders. The change in metabolism is reportedly associated with inadequate response to antianxiety and antidepressant agents. Objective: This study aimed to determine the effect of milnacipran antidepressants on anxiety-like behavior in mice with diabetes mellitus. Methods: Male ICR mice were divided into naive, stress, diabetes mellitus (DM), DM + stress groups to measure anxiety-like behavior. Diabetes mellitus was induced using alloxan, and electric footshock stress was used as a stressor for 14 consecutive days. Anxiety-like behavior was measured using the light-dark box (LDB) and elevated plus maze (EPM) test at days 0, 7 and 14. The antidepressant milnacipran (MIL) was given for 7 days, on days 8 to 14. On day 14, evaluation of anxiety-like behavior after administration of MIL was carried out in all groups using LDB and EPM tests. Results: The results showed that administration of milnacipran effectively ameliorated anxiety-like behavior in the non-DM, but not in the DM group, using the LDB test. A similar result was demonstrated in the EPM test showing the non-DM group's attenuation after milnacipran administration. Conclusion: The present results indicate that there is an inadequate attenuation of the anxiety-like behavior after treatment with milnacipran in diabetes conditions.

[1]  Zilong Gao,et al.  SNRIs achieve faster antidepressant effects than SSRIs by elevating the concentrations of dopamine in the forebrain , 2020, Neuropharmacology.

[2]  Joaquim Azevedo Neto,et al.  Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress , 2020, Psychopharmacology.

[3]  C. Vaillancourt,et al.  Placental serotonin systems in pregnancy metabolic complications associated with maternal obesity and gestational diabetes mellitus. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[4]  L. Yao,et al.  Involvement of the dopamine D1 receptor system in the anxiolytic effect of cedrol in the elevated plus maze and light-dark box tests. , 2019, Journal of pharmacological sciences.

[5]  Jian Zhang,et al.  Fluoxetine Attenuated Anxiety-Like Behaviors in Streptozotocin-Induced Diabetic Mice by Mitigating the Inflammation , 2019, Mediators of inflammation.

[6]  Q. Dong,et al.  Pharmacotherapeutic strategies for managing comorbid depression and diabetes , 2019, Expert opinion on pharmacotherapy.

[7]  C. Garg,et al.  NO-sGC-cGMP signaling influence the anxiolytic like effect of lithium in mice in light and dark box and elevated plus maze , 2019, Brain Research.

[8]  Jin-Hee Seo.  Treadmill exercise alleviates stress-induced anxiety-like behaviors in rats , 2018, Journal of exercise rehabilitation.

[9]  J. McCabe,et al.  Behavior of Male and Female C57BL/6J Mice Is More Consistent with Repeated Trials in the Elevated Zero Maze than in the Elevated Plus Maze , 2017, Front. Behav. Neurosci..

[10]  Hong Nie,et al.  The antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus , 2016, Scientific Reports.

[11]  W. Guo,et al.  Regulation of astrocyte pathology by fluoxetine prevents the deterioration of Alzheimer phenotypes in an APP/PS1 mouse model , 2016, Glia.

[12]  K. Ismail,et al.  The link between depression and diabetes: the search for shared mechanisms. , 2015, The lancet. Diabetes & endocrinology.

[13]  Alyson K. Myers,et al.  Brief report: Depression and history of suicide attempts in adults with new-onset Type 2 Diabetes , 2013, Psychoneuroendocrinology.

[14]  I. Lucki,et al.  Effects of diabetes on hippocampal neurogenesis: Links to cognition and depression , 2013, Neuroscience & Biobehavioral Reviews.

[15]  M. Briley,et al.  The importance of norepinephrine in depression , 2011, Neuropsychiatric disease and treatment.

[16]  C. Kamei,et al.  Assessing anxiolytic-like effects of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors using the elevated plus maze in mice. , 2010, Methods and findings in experimental and clinical pharmacology.

[17]  M. Hascöet,et al.  Anxiolytic-like effect of milnacipran in the four-plate test in mice: Mechanism of action , 2005, Pharmacology Biochemistry and Behavior.

[18]  H. Takeda,et al.  Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm. , 2004, European journal of pharmacology.

[19]  J. Kamei,et al.  Effects of selective serotonin reuptake inhibitors on immobility time in the tail suspension test in streptozotocin-induced diabetic mice , 2003, Pharmacology Biochemistry and Behavior.

[20]  A. Lima,et al.  Increased astrocyte reactivity in the hippocampus of murine models of type 1 diabetes: the nonobese diabetic (NOD) and streptozotocin-treated mice , 2002, Brain Research.

[21]  R. Tsujita,et al.  Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats , 2002, Psychopharmacology.

[22]  C. Lloyd,et al.  Depression and diabetes. , 2002, Current women's health reports.

[23]  Romain Meeusen,et al.  Differential effects of restraint stress on hippocampal 5-HT metabolism and extracellular levels of 5-HT in streptozotocin-diabetic rats , 1997, Brain Research.

[24]  S. Maier,et al.  The elevated plus-maze is not sensitive to the effect of stressor controllability in rats , 1995, Pharmacology Biochemistry and Behavior.

[25]  E. Osim,et al.  CRUDE AQUEOUS LEAVE EXTRACT OF CARICA PAPAYA LINN (PAWPAW) REDUCED ANXIETY AND FEAR RELATED BEHAVIOUR IN CD1 MICE , 2018 .

[26]  O. Akinloye,et al.  Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. , 2017, Medicina.

[27]  望月 大介.  Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats , 2003 .